Pfizer Inc. (NYSE:PFE) Shares Bought by Alpha Omega Wealth Management LLC

Alpha Omega Wealth Management LLC increased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 12.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 149,388 shares of the biopharmaceutical company’s stock after buying an additional 16,875 shares during the quarter. Alpha Omega Wealth Management LLC’s holdings in Pfizer were worth $4,301,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. RB Capital Management LLC grew its holdings in Pfizer by 6.7% during the first quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company’s stock worth $282,000 after acquiring an additional 341 shares during the period. Ironwood Wealth Management LLC. increased its holdings in Pfizer by 1.1% in the first quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company’s stock valued at $1,868,000 after buying an additional 400 shares in the last quarter. United Bank raised its position in shares of Pfizer by 0.6% in the first quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock worth $2,416,000 after acquiring an additional 290 shares during the period. Ergoteles LLC boosted its stake in shares of Pfizer by 136.3% during the 1st quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company’s stock worth $1,903,000 after acquiring an additional 21,209 shares in the last quarter. Finally, Mackenzie Financial Corp grew its position in shares of Pfizer by 6.4% during the 1st quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company’s stock valued at $69,238,000 after acquiring an additional 79,887 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Trading Down 0.8 %

Shares of NYSE PFE traded down $0.22 during midday trading on Wednesday, reaching $25.69. 28,885,313 shares of the stock were exchanged, compared to its average volume of 33,467,946. The stock has a market capitalization of $145.47 billion, a P/E ratio of 71.36, a PEG ratio of 1.18 and a beta of 0.61. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The company has a 50 day simple moving average of $27.23 and a 200 day simple moving average of $28.79. Pfizer Inc. has a twelve month low of $25.61 and a twelve month high of $41.33.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. During the same period in the prior year, the business posted $1.14 EPS. The business’s revenue for the quarter was down 41.3% compared to the same quarter last year. As a group, equities analysts expect that Pfizer Inc. will post 2.22 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have issued reports on PFE shares. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Monday. Guggenheim started coverage on shares of Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective for the company. Finally, TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a research report on Thursday, January 4th. Twelve analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $36.88.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.